Emvistegrast has the potential to be a best-in-class oral for patients with ulcerative colitis,
interview with STAT
“Patients with inflammatory bowel disease, while they have other therapies available, still have persistent symptoms. A majority do not achieve remission, so seeing these data was…”
“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”